Publications

Ruan J, Bond DA, Shah B, Allan JN, Rutherford SC, Gribbin C, Chen Z, Bhinder B, Tam W, Rossi D et al..  2026.  MRD-driven initial therapy of acalabrutinib and lenalidomide plus rituximab or obinutuzumab for mantle cell lymphoma.. Blood Adv. 10(4):1381-1394.

Ruan J, Bond DA, Shah BD, Allan JN, Rutherford SC, Gribbin C, Chen Z, Bhinder B, Tam W, Rossi D et al..  2025.  MRD-driven Initial Therapy of Acalabrutinib and Lenalidomide plus Rituximab (ALR) or Obinutuzumab (ALO) for Mantle Cell Lymphoma.. Blood Adv.

Ruan J, Moskowitz A, Mehta-Shah N, Sokol L, Chen Z, Kotlov N, Nos G, Sorokina M, Maksimov V, Sboner A et al..  2023.  Multicenter phase 2 study of oral azacitidine (CC-486) plus CHOP as initial treatment for PTCL.. Blood. 141(18):2194-2205.

Shah MA, Enzinger P, Ko AH, Ocean AJ, Philip PAgop, Thakkar PV, Cleveland K, Lu Y, Kortmansky J, Christos PJ et al..  2020.  Multicenter Phase II Study of Cabazitaxel in Advanced Gastroesophageal Cancer: Association of HER2 Expression and M2-Like Tumor-Associated Macrophages with Patient Outcome.. Clin Cancer Res. 26(18):4756-4766.

Surapaneni S, Kutler RB, Setzen SA, Kim YEun, Yao P, Siddiqui SH, Pitman MJ, Sulica L, Elemento O, Khosravi P et al..  2026.  A Multimodal Approach for Deep-Learning Classification of Vocal Fold Pathologies in Stroboscopy.. Laryngoscope.

Scarpa JR, Elemento O.  2023.  Multi-omic molecular profiling and network biology for precision anaesthesiology: a narrative review.. Br J Anaesth. 131(1):26-36.

Bojmar L, Zambirinis CP, Hernandez JM, Chakraborty J, Shaashua L, Kim J, Johnson KEnnu, Hanna S, Askan G, Burman J et al..  2024.  Multi-parametric atlas of the pre-metastatic liver for prediction of metastatic outcome in early-stage pancreatic cancer.. Nat Med. 30(8):2170-2180.

Bunting KL, T Soong D, Singh R, Jiang Y, Béguelin W, Poloway DW, Swed BL, Hatzi K, Reisacher W, Teater M et al..  2016.  Multi-tiered Reorganization of the Genome during B Cell Affinity Maturation Anchored by a Germinal Center-Specific Locus Control Region.. Immunity. 45(3):497-512.

Béguelin W, Teater M, Meydan C, Hoehn KB, Phillip JM, Soshnev AA, Venturutti L, Rivas MA, Calvo-Fernández MT, Gutierrez J et al..  2020.  Mutant EZH2 Induces a Pre-malignant Lymphoma Niche by Reprogramming the Immune Response.. Cancer Cell. 37(5):655-673.e11.

Nie K, Redmond D, Eng KW, Zhang T, Cheng S, Mathew S, Elemento O, Tam W.  2021.  Mutation landscape, clonal evolution pattern, and potential pathogenic pathways in B-lymphoblastic transformation of follicular lymphoma.. Leukemia. 35(4):1203-1208.

Mlynarczyk C, Teater M, Pae J, Chin CR, Wang L, Arulraj T, Barisic D, Papin A, Hoehn KB, Kots E et al..  2023.   mutation yields supercompetitive B cells primed for malignant transformation.. Science. 379(6629):eabj7412.

Rajadhyaksha AM, Elemento O, Puffenberger EG, Schierberl KC, Xiang JZ, Putorti ML, Berciano J, Poulin C, Brais B, Michaelides M et al..  2010.  Mutations in FLVCR1 cause posterior column ataxia and retinitis pigmentosa.. Am J Hum Genet. 87(5):643-54.

Altorki NK, Walsh ZH, Melms JC, Port JL, Lee BE, Nasar A, Spinelli C, Caprio L, Rogava M, Ho P et al..  2023.  Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I-III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial.. Nat Commun. 14(1):8435.

Altorki NK, McGraw TE, Borczuk AC, Saxena A, Port JL, Stiles BM, Lee BE, Sanfilippo NJ, Scheff RJ, Pua BB et al..  2021.  Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial.. Lancet Oncol. 22(6):824-835.

Podaza E, Kuo H-H, Nguyen J, Elemento O, M Martin L.  2022.  Next generation patient derived tumor organoids.. Transl Res. 250:84-97.

Pisapia DJ, Salvatore S, Pauli C, Hissong E, Eng K, Prandi D, Sailer V-W, Robinson BD, Park K, Cyrta J et al..  2017.  Next-Generation Rapid Autopsies Enable Tumor Evolution Tracking and Generation of Preclinical Models.. JCO Precis Oncol. 2017

Chang C-Y, H Pasolli A, Giannopoulou EG, Guasch G, Gronostajski RM, Elemento O, Fuchs E.  2013.  NFIB is a governor of epithelial-melanocyte stem cell behaviour in a shared niche.. Nature. 495(7439):98-102.

Hu Y, Bloy N, Elemento O, Buqué A.  2022.  Nicotinamide drives T cell activation in the mammary tumor microenvironment.. J Transl Med. 20(1):251.

Hissong E, Assaad MAl, Bal M, Reed KA, Fornelli A, Levine MF, Gundem G, Semaan A, Orr CE, Sakhadeo U et al..  2024.  NIPBL::NACC1 Fusion Hepatic Carcinoma.. Am J Surg Pathol. 48(2):183-193.

Dardenne E, Beltran H, Benelli M, Gayvert K, Berger A, Puca L, Cyrta J, Sboner A, Noorzad Z, MacDonald T et al..  2016.  N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer.. Cancer Cell. 30(4):563-577.

Berger A, Brady NJ, Bareja R, Robinson B, Conteduca V, Augello MA, Puca L, Ahmed A, Dardenne E, Lu X et al..  2019.  N-Myc-mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancer.. J Clin Invest. 129(9):3924-3940.

Barnes J, Brendel M, Gao VR, Rajendran S, Kim J, Li Q, Malmsten JE, Sierra JT, Zisimopoulos P, Sigaras A et al..  2023.  A non-invasive artificial intelligence approach for the prediction of human blastocyst ploidy: a retrospective model development and validation study.. Lancet Digit Health. 5(1):e28-e40.

Franceschini GMarco, Quaini O, Mizuno K, Orlando F, Ciani Y, Ku S-Y, Sigouros M, Rothmann E, Alonso A, Benelli M et al..  2024.  Noninvasive Detection of Neuroendocrine Prostate Cancer through Targeted Cell-free DNA Methylation.. Cancer Discov. 14(3):424-445.

Lu Y, T Soong D, Elemento O.  2013.  A novel approach for characterizing microsatellite instability in cancer cells.. PLoS One. 8(5):e63056.

Alsaleem MA, Ball G, Toss MS, Raafat S, Aleskandarany M, Joseph C, Ogden A, Bhattarai S, Rida PCG, Khani F et al..  2020.  A novel prognostic two-gene signature for triple negative breast cancer.. Mod Pathol.